Dr. Hammers on Challenges With CAR T-Cell Therapy in RCC

Video

Hans Hammers, MD, PhD, associate professor of internal medicine, Division of Hematology-Oncology, UT Southwestern Medical Center, discusses the challenges with using CAR T-cell therapy in renal cell carcinoma.

Hans Hammers, MD, PhD, associate professor of internal medicine, Division of Hematology-Oncology, UT Southwestern Medical Center, discusses the challenges with CAR T-cell therapy in renal cell carcinoma (RCC).

The introduction of CAR T cells has been practice changing in hematologic malignancies. More success has been seen in leukemia compared with solid tumors like RCC, says Hammers. In leukemia, CAR T-cell therapy typically depletes B cells, but a similar antigen target is not as easy to find in solid tumors. Approaches that increase the specificity of tumor cells and the resistance to the tumor microenvironment may be the key to utilizing CAR T cells more effectively in solid tumors.

Hammers is hopeful that present developments in other diseases will shed light on kidney cancer treatment in the near future.

Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
© 2024 MJH Life Sciences

All rights reserved.